Could EMA and cytokeratin 7 be useful in distinguishing tricholemmal carcinoma from clear-cell squamous cell carcinoma? A case series from our department and a brief review of the literature

2019 ◽  
Vol 121 (6) ◽  
pp. 765-767 ◽  
Author(s):  
Costantino Ricci ◽  
Emi Dika ◽  
Doriana Donatella Di Nanni ◽  
Guido Zannetti ◽  
Martina Lambertini ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Clear Cell ◽  
Case Series ◽  
Cytokeratin 7 ◽  
Review Of The Literature

Squamous cell carcinoma arising in mature cystic teratoma of the ovary: A case series and review of the literature

2007 ◽  
Vol 105 (2) ◽  
pp. 321-324 ◽  
Author(s):  
Lisa Dos Santos ◽  
Evelyn Mok ◽  
Alexia Iasonos ◽  
Kay Park ◽  
Robert A. Soslow ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Case Series ◽  
Cystic Teratoma ◽  
Mature Cystic Teratoma ◽  
Review Of The Literature

scholarly journals Clear Cell Squamous Cell Carcinoma: Clinical and Histologic Parameters and a Review of the Literature

2020 ◽  
Vol 4 (2) ◽  
pp. 130
Author(s):  
Mathew Loesch ◽  
Stephen J Ganocy ◽  
Christine Jaworsky
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Clear Cell ◽  
Review Of The Literature ◽  
History Of ◽  
Age Range ◽  
Anatomic Region ◽  
Clear Cell Change

Background: Clear cell squamous cell carcinoma (ccSCC) is an uncommon subtype of squamous cell carcinoma. This tumor subtype arises more commonly in elderly individuals and occurring greater upon sun-exposed areas of the body.Objective: To determine the age range and locations of ccSCC, and occurrence in men as compared with women.Methods: An observational study of ccSCC accessioned at a dermatopathology laboratory (Cleveland Skin Pathology, CSP) over an 18-month interval. Cases were retrieved and included based on a search of the terms “clear cell squamous cell carcinoma” in the diagnosis field of the CSP database and reviewed for accuracy and the degree of clear cell change in each lesion. Pathology requisition forms from these cases were used only to identify patients’ age, gender, and anatomic region of the ccSCC reviewed.Results: Of the 17,838 cases of in situ and invasive SCC, there were a total of 107 ccSCC, 77 in situ and 30 invasive (0.6% of total SCC). Of patients with ccSCC, 71% had a history of skin cancer, many (57.9%) in the same anatomic region. When the degree of clear cell change was evaluated there was no statistically significant increase of percentage clear cell change in tumors with age.Conclusions: Along with confirming past observations made with previous studies, our series shows that more men than women develop such tumors before 70 years of age, and more women than men after 70 years of age with men developing ccSCC on average 7 years earlier than women.

scholarly journals Local Chemotherapy as an Adjuvant Treatment in Unresectable Squamous Cell Carcinoma: What Do We Know So Far?

2021 ◽  
Vol 28 (4) ◽  
pp. 2317-2325
Author(s):  
Luigi Bennardo ◽  
Francesco Bennardo ◽  
Amerigo Giudice ◽  
Maria Passante ◽  
Stefano Dastoli ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Gold Standard ◽  
Systemic Chemotherapy ◽  
Standard Treatment ◽  
Case Reports ◽  
Case Series ◽  
Surgical Removal ◽  
Local Chemotherapy

Background: Squamous cell carcinoma (SCC) is one of the most common cancers involving skin and oral mucosa. Although this condition’s gold-standard treatment is the surgical removal of the lesions, the physician must propose alternative treatments in some cases due to the patient’s ineligibility for surgery. Among the available alternative therapies, local chemotherapy may represent an initial treatment in combination with radiotherapy or systemic chemotherapy due to the low frequency of side-effects and the lack of necessity for expensive devices. Methods: In this paper, we review all available literature in various databases (PubMed, Scopus-Embase, Web of Science), proposing local chemotherapy as a treatment for cutaneous and oral SCC. Exclusion criteria included ocular lesions (where topical treatments are common), non-English language, and non-human studies. Results: We included 14 studies in this review. The majority were case reports and case series describing the treatment of non-resectable localized SCC with either imiquimod or 5-fluorouracil. We also analyzed small studies proposing combination treatments. Almost all studies reported an excellent clinical outcome, with a low risk of relapses in time. Conclusions: Resection of the lesion remains the gold-standard treatment for SCC. When this approach is not feasible, local chemotherapy may represent a treatment alternative, and it may also be associated with radiotherapy or systemic chemotherapy.

scholarly journals Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Jeffrey A. How ◽  
Amir A. Jazaeri ◽  
Pamela T. Soliman ◽  
Nicole D. Fleming ◽  
Jing Gong ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Squamous Cell ◽  
Single Agent ◽  
Case Series ◽  
Predictive Biomarkers ◽  
Vulvar Squamous Cell Carcinoma ◽  
Metastatic Setting ◽  
Progression Of Disease

AbstractVaginal and vulvar squamous cell carcinoma (SCC) are rare tumors that can be challenging to treat in the recurrent or metastatic setting. We present a case series of patients with vaginal or vulvar SCC who were treated with single-agent pembrolizumab as part of a phase II basket clinical trial to evaluate efficacy and safety. Two cases of recurrent and metastatic vaginal SCC, with multiple prior lines of systemic chemotherapy and radiation, received pembrolizumab. One patient had significant reduction (81%) in target tumor lesions prior to treatment discontinuation at cycle 10 following confirmed progression of disease with new metastatic lesions (stable disease by irRECIST criteria). In contrast, the other patient with vaginal SCC discontinued treatment after cycle 3 due to disease progression. Both patients had PD-L1 positive vaginal tumors and tolerated treatment well. One case of recurrent vulvar SCC with multiple surgical resections and prior progression on systemic carboplatin had a 30% reduction in her target tumor lesions following pembrolizumab treatment with a PD-L1 positive tumor. Treatment was discontinued for grade 3 mucositis after cycle 5. Pembrolizumab may provide some clinical benefit to some patients with vaginal or vulvar SCC and is overall safe to utilize in this population. Future studies are needed to evaluate the efficacy of pembrolizumab in these rare tumor types and to identify predictive biomarkers of response.

Sign in / Sign up

Export Citation Format

Share Document